Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: A randomized, double-blind, placebo-controlled study

Archives of Dermatology

Volumn 148, Issue 3, 2012, Pages 307-314

  Tee, Shang Ian ^a   Yosipovitch, Gil ^f   Chan, Yuin Chew ^b   Chua, Sze Hon ^a   Koh, Ee Tzun ^c   Chan, Yiong Huak ^d   Tan, Susanna Soo See ^c   Tsou, Ian Yu Yan ^e   Tan, Suat Hoon ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

^b Dermatology Associates   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; PLACEBO;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE SKIN DISEASE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FEMUR NECK; HEADACHE; HUMAN; LUMBAR SPINE; MALE; MUSCULOSKELETAL PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGAPORE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ALENDRONATE; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS; PEMPHIGUS; PREDNISOLONE; PROSPECTIVE STUDIES; SINGAPORE; SKIN DISEASES, VESICULOBULLOUS; VITAMIN D;

EID: 84858722483     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.354     Document Type: Article

References (44)

1. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383-1389. (Pubitemid 32045866)
2. Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Arch Dermatol. 2001;137(4):477-481. (Pubitemid 32319844)
3. Summey BT, Yosipovitch G. Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol. 2006;142(1):82-90. (Pubitemid 43107366)
4. Wohl Y, Dreiher J, Cohen AD. Pemphigus and osteoporosis: a case-control study. Arch Dermatol. 2010;146(10):1126-1131.
5. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515-1526.
6. Lei SF, Chen Y, Xiong DH, Li LM, Deng HW. Ethnic difference in osteoporosis-related phenotypes and its potential underlying genetic determination. J Musculoskelet Neuronal Interact. 2006;6(1):36-46. (Pubitemid 43732827)
7. van Kuijk C, Genant HK. Radiological aspects. In: Riggs BL, Melton LJ III, eds. Osteoporosis: Etiology, Diagnosis and Management. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1995:249-273.
8. Kanis JA; WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4(6):368-381.
9. Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP; British Association of Dermatologists. Guidelines for the management of bullous pemphigoid. Br J Dermatol. 2002;147(2):214-221.
10. Dick SE, Werth VP. Pemphigus: a treatment update. Autoimmunity. 2006;39(7): 591-599. (Pubitemid 44768928)
11. Wong SN, Chua SH. Bullous pemphigoid seen at the National Skin Centre: a 2-year retrospective review. Ann Acad Med Singapore. 2002;31(2):170-174.
12. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319- 1328. (Pubitemid 47389469)
13. Lems WF. Bisphosphonates in patients with glucocorticoids: time for implementation. J Rheumatol. 2009;36(8):1570-1572.
14. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893-899. (Pubitemid 41103445)
15. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777-787. (Pubitemid 36336722)
16. Saag KG, Emkey R, Schnitzer TJ, et al Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339(5):292-299. (Pubitemid 28366417)
17. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337(6):382-387. (Pubitemid 27328368)
18. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6(2):82-88.
19. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003;5(1):65-74.
20. Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev. 2000;(2):CD001347.
21. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14(9):605-615.
22. Wasnich RD, Ross PD, Thompson DE, Cizza G, Yates AJ. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteoporos Int. 1999;9(5):455-460. (Pubitemid 29231739)
23. Ravn P, Clemmesen B, Christiansen C; Alendronate Osteoporosis Prevention Study Group. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone. 1999;24(3):237-244. (Pubitemid 29094566)
24. Lems WF, Lodder MC, Lips P, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int. 2006;17(5):716-723.
25. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44(1):202-211. (Pubitemid 32113136)
26. Yan Y, Wang W, Zhu H, et al. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. J Bone Miner Metab. 2009;27(4):471-478.
27. Furukawa F, Kaminaka C, Ikeda T, et al Wakayama Study Group on Dermatological Use of Bisphosphonates. Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy. Clin Exp Dermatol. 2011;36(2):165-168. doi:10.1111/j.1365-2230.2010. 03856.x.
28. Iwamoto J, Takeda T, Sato Y, Uzawa M. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. Yonsei Med J. 2005;46(6):750-758. (Pubitemid 43085176)
29. Guañabens N, Parés A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98(10):2268-2274.
30. Amin S, LaValley MP, Simms RW, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. 1999;42(8): 1740-1751. (Pubitemid 30263645)
31. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial: European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15(6):1006-1013. (Pubitemid 30350063)
32. Liu RH, Albrecht J, Werth VP. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol. 2006;142(1):37-41. (Pubitemid 43107359)
33. Stratman EJ. Underutilization of prophylaxis for osteoporosis: comment on "pemphigus and osteoporosis." Arch Dermatol. 2010;146(10):1131.
34. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci. 2011;1218(1):38-46.
35. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010;304(13):1480-1484.
36. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728-1737.
37. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165(3):346-347. (Pubitemid 40216293)
38. McNicholl DM, Heaney LG. The safety of bisphosphonate use in premenopausal women on corticosteroids. Curr Drug Saf. 2010;5(2):182-187.
39. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008;30(12): 1146-1148.
40. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.
41. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42(11):2309-2318. (Pubitemid 30333410)
42. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277-285.
43. Reid DM, Devogelaer JP, Saag K, et al; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253-1263.
44. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003; 14(10):801-807. (Pubitemid 37462129)